Endeavor BioMedicines’ Post

RAWNY is proud of our robust clinical research department and our ongoing mission to help discover improved therapies for retinal diseases. We are now enrolling patients in EYP-1901 LUGANO, a clinical research trial for wet age-related macular degeneration. If you're interested in participating in a clinical trial, talk to your doctor to see if you may qualify. Learn more about this trial by visiting https://lnkd.in/d5KkptMa #clinicalresearch #clinicalresearchtrial #maculardegeneration #wetmaculardegeneration #AMD #retina #retinaspecialist #ophthalmology #retinaldisease #retinalresearch

Have you ever heard of bacteriophage therapy for recurrent UTI? Research has shown great promise in this area, and we're excited to announce that a clinical trial is planned for 2025. To provide more insight into phage therapy and how PHIOGEN's new phage products work, Amanda (Curtis) Burkardt and Mayukh Das discussed the following questions in our recent video interview: 👉 What is bacteriophage therapy? 👉 Could phage therapy be used anywhere in the body, for instance, the bladder, vagina or respiratory system? 👉 Does there need to be a certain level of bacteria present in order for phage therapy to work? 👉 Can they kill bacteria embedded within the bladder wall, or in biofilms? 👉 What makes someone more or less likely to be a good candidate for phage therapy? 👉 Do you need to be able to culture someone’s infection in order to develop the right phages for therapy? 👉 How long does it take to eradicate a chronic UTI with phage therapy? 👉 Are there any potential side effects of phage therapy? 👉 Can phages negatively impact the good organisms in the normal microbiome? 👉 How will people be able to participate in PHIOGEN’s clinical trial? Watch the full interview over on YouTube: https://lnkd.in/ewQDcyNb

#transcript Dr. Abu Abraham, CMO at Cloudbreak Pharma,  discusses the disease burden and gaps in care for patients with Pterygium, also known as Surfer's eye. Pterygium is an ocular surface disorder that creates a growth on the eye's surface that can cause vision problems. The condition is more prevalent in individuals over 40, but it can also affect younger populations exposed to risk factors from spending time outside in the sun and being exposed to UV light. Cloudbreak Pharma is developing CBT-001, an investigational therapy, a multi-kinase inhibitor administered as an eye drop that aims to stop the progression of Pterygium. #OcularDisease #OcularExternalDisease CloudbreakPharma.com https://lnkd.in/g5Q4ArEH

Want to learn more about the work we are doing behind the scenes at PHIOGEN? Curious about what a clinical trial for recurrent UTIs looks like with phage as a treatment? Watch out interview below with our CEO Amanda (Curtis) Burkardt and COO Mayukh Das and see if you qualify for the survey to help us develop products that are patient centric!

Partnering to Develop New Treatments Did you know that diabetes affects an estimated 9.4 percent of all Canadians and can result in potentially life-threatening complications? One of the complications that often develops is diabetic kidney disease (DKD), which is the leading cause of kidney failure in North America. Thankfully, clinician-scientists within the Hamilton Centre for Kidney Research at St. Joseph's Healthcare Hamilton are working on solutions. Dr. Joan Krepinsky and her team have uncovered a novel biological mechanism of DKD that has led them to a promising therapeutic target. They are currently collaborating with Novo Nordisk and the Empire Discovery Institute in the LeapRX program to develop a peptide treatment that may help prevent DKD from progressing. 📖 Learn more about the project in our 2023-2024 Annual Report: https://bit.ly/4gpsnlU #WeAreStJoes #DedicatedToDiscovery

Different Autoantibody Phenotypes in Juvenile and Adult Myositis A Kyoto University study compared juvenile-idiopathic inflammatory myopathy (IIM) and adult-IIM patients, demonstrating different autoantibody profiles and a more favorable outcome for n juvenile-IIM patients. https://buff.ly/3XtN5ch

💊 Although endocrine therapies are vital in treating patients with HR+, HER2- #MetastaticBreastCancer, patients may still face ET resistance and disease progression. 🔬Current clinical trials are focused on investigating novel approaches to block the estrogen pathway. These advancements aim to maximize endocrine pathway antagonism while enhancing the drug-like properties. 👉Click to explore these scientific advancements: https://e.lilly/4gf8DRS #BreastCancerResearch #BCSM #PatientCare

Patients with central neoplasms and haemoptysis show low survival rates. Bleeding control without recurrence 48 hours after bronchoscopic interventions may improve the prognosis of these patients. Bronchoscopic Argon Plasma Coagulation (APC) is a useful technique for endobronchial management of haemoptysis in these patients. Nevertheless, limited data are available in the literature on its efficacy and safety and the main predictors of success are still unclear. We are glad to share the findings of our recent study which demonstrates that bronchoscopic APC is a safe and effective procedure in the treatment of patients with haemoptysis caused by endobronchial malignancies, regardless of the clinical characteristics of the patients, the endoscopic and histological features of the neoplasm and the severity of the symptom. #Bronchoscopy #LungCancer #ArgonPlasmaCoagulation #APC #Haemoptysis

Different Autoantibody Phenotypes in Juvenile and Adult Myositis A Kyoto University study compared juvenile-idiopathic inflammatory myopathy (IIM) and adult-IIM patients, demonstrating different autoantibody profiles and a more favorable outcome for n juvenile-IIM patients. https://buff.ly/4eua4Lb